Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration

被引:20
作者
Ehrlich, A
Lücker, PW
Wiedemann, A
Sander, P
Huber, R
Mascher, H
机构
[1] BYK Gulden Lomberg Chem Fabrik GmbH, D-78467 Constance, Germany
[2] Prof Dr Lucker GmbH, Inst Klin Pharmakol, Grunstadt, Germany
[3] Pharm Analyt Lab GmbH, Baden, Austria
来源
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY | 1999年 / 21卷 / 01期
关键词
pantoprazole; omeprazole MUPS; intragastric pH; healthy volunteers;
D O I
10.1358/mf.1999.21.1.527018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects on intragastric pH and gastrin secretion of once daily pantoprazole (40 mg) and a new formulation omeprazole (20 mg) in a Multiple Unit Pellet System (MUPS) were investigated during two treatment periods of 7 days each in a randomized crossover study with 16 healthy Helicobacter pylori-negative male volunteers. Intragastric pH was measured using continuous 24 hour pH-metry on days 1 and 7. The results were compared to the baseline curves obtained before each treatment period. On day 1, pantoprazole raised the intragastric pH significantly higher and more quickly than omeprazole MUPS (pH median 1.9 vs. 1.6, baseline pH 1.4). After 7 days, the 24 h gastric pH medians were still in favor of pantoprazole (pH 3.0 vs. 2.8). With respect to the basal gastrin concentration, both treatments resulted in similar increases. For pantoprazole, no differences were observed in A UC and C-max after single and repeated dosing. However, the new omeprazole MUPS formulation still showed the well-known effect of initial low bioavailability increasing after repeated dosing. Pantoprazole and omeprazole were well tolerated. There seems to be no advantage in the new omeprazole formulation compared with the conventional capsule with regard to bioavailability and increase in intragastric pH. The results of this this study confirm former results in which pantoprazole (40 mg) was shown to be significantly superior to omeprazole (20 mg) in elevating intragastric pH. (C) 1999 Prous Science. All rights reserved.
引用
收藏
页码:47 / 51
页数:5
相关论文
共 25 条
[1]  
ANDERSSON T, 1990, Drug Investigation, V2, P184
[2]   INFLUENCE OF ACID SECRETORY STATUS ON ABSORPTION OF OMEPRAZOLE FROM ENTERIC COATED GRANULES [J].
ANDERSSON, T ;
BERGSTRAND, R ;
CEDERBERG, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (03) :275-278
[3]   PHARMACOKINETICS AND BIOAVAILABILITY OF OMEPRAZOLE AFTER SINGLE AND REPEATED ORAL-ADMINISTRATION IN HEALTHY-SUBJECTS [J].
ANDERSSON, T ;
ANDREN, K ;
CEDERBERG, C ;
LAGERSTROM, PO ;
LUNDBORG, P ;
SKANBERG, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (05) :557-563
[4]  
ANDERSSON T, 1991, Drug Investigation, V3, P45
[5]  
BOCHENEK W, 1998, DIGESTION S3, V59, P601
[6]  
Brunner G, 1997, GASTROENTEROLOGY, V112, pA78
[7]   OMEPRAZOLE - PHARMACOKINETICS AND METABOLISM IN MAN [J].
CEDERBERG, C ;
ANDERSSON, T ;
SKANBERG, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :33-42
[8]  
DAMMANN HG, 1994, ALIMENT PHARM THERAP, V8, P549
[9]   Pantoprazole - A review of its pharmacological properties and therapeutic use in acid-related disorders [J].
Fitton, A ;
Wiseman, L .
DRUGS, 1996, 51 (03) :460-482
[10]   Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole [J].
Hartmann, M ;
Theiss, U ;
Huber, R ;
Luhmann, R ;
Bliesath, H ;
Wurst, W ;
Lucker, PW .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (03) :359-366